Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

Inclusion Criteria:

• Have underlying HeFH and/or a history of ASCVD or multiple ASCVD risk factors

• On maximally tolerated lipid-modifying therapy as an adjunct to a diet and lifestylemodifications

• LDL-C ≥ 70 mg/dL

• Triglycerides < 500

• Estimated glomerular filtration rate ≥ 15 mL/min/1.73 m2

Exclusion Criteria:

• History of New York Heart Association (NYHA) class III or IV heart failure of leftventricular ejection fraction <30%

• Hospitalized for heart failure within the last 5 years

• Myocardial infarction, stroke, non-elective coronary revascularization orhospitalization for unstable angina or chest pain in the last 3 months

• Uncontrolled severe hypertension

• Diagnosis of homozygous FH

• Liver disease

• HbA1c ≥ 10.0% or fasting glucose ≥ 270 mg/dL

• Thyroid-stimulating hormone >1.5 x upper limit of normal (ULN)

• History of malignancy

• Creatinine kinase (CK) >3 X ULN

• Alcohol abuse

• Treatment with investigational product

• Treatment with gemfibrozil or ezetimibe

• Previous participation in a trial evaluating obicetrapib

• Known allergy to study drugs, placebo or excipients in study drugs of placebo

• Other condition that would interfere with the conduct of the study